As a 36-kDa endogenous protein, Annexin A5 (AnxA5, ANXV, Annexin V) belongs to a family of 12 ubiquitously expressed proteins and offers anticoagulant, anti-inflammatory and anti-apoptotic properties. Its ability to associate specifically with phosphatidylserine (PS) has been demonstrated in vitro and become a strong tool to detect apoptosis. In addition, Annexin A5 reduces inflammation and endothelial activation, thereby improving nitric oxide signaling and vascular endothelial function. These properties enable it to be a promising therapeutic agent to attenuate the effects of endothelial damage in sepsis.
Potential Appliactions of Annexin A5
Annexin A5 as Therapeutics
Annexin A5 reduces thrombin production evoked by central glaucomatous ligaments, a clinically related model of sepsis. Annexin A5’ is effective in preclinical models of sepsis, while its potential as a therapeutic method to treat patients with sepsis has not been explored.
Annexin A5 (ANXV), produced recombinantly in Escherichia coli (E. coli), is a novel drug containing human annexin A5 protein. ANXV protects cells like endogenous annexin A5 can inhibit adhesion and affect immune cell activity. Thus, ANVX provides a promising therapeutic agent.
Annexin A5 as in vivo Imaging Probes
Several annexin A5 imaging probes have demonstrated their safety in human imaging studies. Through assessing apoptosis of tumor cells after treatment, it has been used to image apoptosis in a variety of diseases (e.g., cardiovascular disease, allograft transplant rejection, and evaluation of cancer treatment efficacy).
Annexin A5 as Reagent
Annexin A5 is commonly employed as a non-quantitative probe for the detection of cells expressing phosphatidylserine (PS) on the cell surface, which is a marker for apoptosis.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Annexin A5
Annexin A5 Pipelines
|
Generic Name
|
Brand Name/
Alternative Name
|
Indications
|
Manufacturer
|
Latest Stage
|
|
Dentonin
|
TPX-100, D-00006, AC-100, BBB-006, TPX-100, DTN
|
Osteoarthritis
|
OrthoTrophix, Inc.
|
Phase II
|
|
GPRI001
|
AC-100- AC-100-Albumin fusion protein
|
Osteoarthritis
|
Guangzhou general pharma
|
Pre-clinical
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
